Real World Evidence in Action

Rodrigo Salas Benavides
Real world evidence

We need to use real world data in order to assess patient outcomes and to ensure that patients get treatment that is right for them.
What do we do?

- Collect data from patients
- Follow up frequently and empower patients with information so they can take control of the disease
- Generate data so we understand better the development of the disease in our countries
Results

- Registry of 528 patients
- 2 posters in medical events
- 2 papers published and 3 ongoing
Internal Outcomes

- Follow up patients
- Managing side effects (Increase overall survival)
- Pharmacovigilance
- Individual Access to treatments
External Outcomes

- Impulse a local cancer patient registry
- Partial approval of the disease in the public health system
- Scientific knowledge
- Cross-collaboration with physicians
Impulse a local cancer patient registry

- A proposal to amend the Health Law was prepared and approved
- Budget was obtained through lobbying with authorities
- Collaboration of national agents in coordination with local authorities to start the work of a population-based cancer registry in one of the most important cities in Mexico
Partial approval of the disease in the public health system

- Obtain reliable information regarding costs and treatments for GIST patients
- Delivered a dossier with information and evidence about GIST patients where the coverage of the condition in the public health care system was requested to the national health sector authorities
- Lobbying and support from different authorities (Including deputies, senators, academics, directors of Universities and all the members of the Commission to Define Treatments and Drugs Associated with Diseases Catastrophic Expenses).
<table>
<thead>
<tr>
<th>Poster/Document</th>
<th>Status</th>
<th>Year</th>
</tr>
</thead>
<tbody>
<tr>
<td>Epidemiological study of 414 Gastrointestinal stromal tumors (GIST) Mexican patients.</td>
<td>Poster.- ESMO 2017 Dr. Calderillo</td>
<td>2017</td>
</tr>
<tr>
<td>Prognostic factors of recurrence and survival of Gastrointestinal Stromal Tumors.</td>
<td>Poster.- ASCO 2017 Dr. Medrano</td>
<td>2017</td>
</tr>
<tr>
<td>Evaluation of quality of life, anxiety, depression and fatigue in patients with GIST.</td>
<td>Aproved in the Journal Psycho-Oncology</td>
<td>2017</td>
</tr>
<tr>
<td>Global survival related to gender and Marital status in patients with GIST.</td>
<td>In process of review with the Mexican Journal of Medicine</td>
<td>2018</td>
</tr>
<tr>
<td>Nutritional risk as a prognostic factor in the Global survival of patients with GIST.</td>
<td>Sent and in process of review to the Journal of Clinical Nutrition</td>
<td>2018</td>
</tr>
</tbody>
</table>
Cross-collaboration with physicians

- 55 specialists refer patients
- Special collaboration to publish with researchers at a national level such as Dr. Germán Calderillo, Dr. Absalón Espinosa, Dr. Rafael Medrano, among others.
Thank you!